
Upadacitinib repigments ~1 in 5 with vitiligo vs 6% placebo
Shownotes
Editor's Pick: Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies (The Lancet, 2026)
Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning the expanding reach of oral JAK inhibitors into vitiligo and alopecia areata, safety and risk stratification at the intersection of skin disease and cancer, and evolving standards for how we define and deliver care in atopic dermatitis and scarring. Let's dive in.
This week's papers:
- Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies.. The Lancet 2026
- Upadacitinib for Severe Alopecia Areata in Adults and Adolescents: Two Phase 3 UP-AA Randomized Clinical Trials.. JAMA Dermatology 2026
- Targeted therapies for psoriasis and atopic dermatitis in the context of malignancy: SPIN-FRT recommendations.. Journal of the European Academy of Dermatology and Venereology 2026
- Alopecia areata as a sentinel condition for systemic autoimmunity: a global bidirectional cohort study.. Dermatology 2026
- Risk Stratification Models for Cutaneous Malignant Neoplasms After Blood or Marrow Transplant.. JAMA Dermatology 2026
- Relapse of Alopecia Areata During Ongoing JAK Inhibitor Therapy Is Not Uncommon and Usually Occurs in Previously Affected Areas: A Multicentre Italian Real-World Study.. Journal of the American Academy of Dermatology 2026
- Real-world Effectiveness and Safety of Lebrikizumab in Atopic Dermatitis: A TREATgermany Analysis.. Acta Dermato-Venereologica 2026
- Redefining Treat-to-target in Atopic Dermatitis: Towards Meaningful, Patient-centred Disease Control - An ISAD Position Paper.. Acta Dermato-Venereologica 2026
- Consensus on energy-based devices for keloids and hypertrophic scars: A Latin American Delphi study.. Journal of the European Academy of Dermatology and Venereology 2026
- Immunosuppression Outweighs Clinical AEIOU Heuristics in Predicting Disease Progression of Merkel Cell Carcinoma: A Retrospective Cohort Study.. Acta Dermato-Venereologica 2026